Shoulder Innovations launches InSet I-135RFX Humeral Stem with expanded fracture indications

SHOULDER INNOVATIONS, INC.

Full commercial launch of InSet I-135RFX Humeral Stem after limited market release and FDA 510(k) clearance for fracture indications.
Product now indicated for primary, revision, and fracture total shoulder arthroplasty.
Third addition to I-Series humeral stem line in three years, following InSet 95 (2024) and InSet 70 (2025).
CEO Rob Ball says launch supports full spectrum of shoulder arthroplasty procedures.
Built on InSet lateral-lateral implant philosophy shown to reduce complications and improve range of motion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.